share_log

Why You Might Be Interested In ZhuZhou QianJin Pharmaceutical Co.,Ltd (SHSE:600479) For Its Upcoming Dividend

Why You Might Be Interested In ZhuZhou QianJin Pharmaceutical Co.,Ltd (SHSE:600479) For Its Upcoming Dividend

为什么你可能对千金药业(SHSE:600479)即将到来的股息感兴趣
Simply Wall St ·  06/24 18:32

It looks like ZhuZhou QianJin Pharmaceutical Co.,Ltd (SHSE:600479) is about to go ex-dividend in the next 2 days. The ex-dividend date is one business day before a company's record date, which is the date on which the company determines which shareholders are entitled to receive a dividend. It is important to be aware of the ex-dividend date because any trade on the stock needs to have been settled on or before the record date. Therefore, if you purchase ZhuZhou QianJin PharmaceuticalLtd's shares on or after the 27th of June, you won't be eligible to receive the dividend, when it is paid on the 27th of June.

千金药业(SHSE:600479)看来即将在未来2天内进行分红派息。分红派息日期是公司公布决定哪些股东有权获得分红的日期前1个营业日。了解分红派息日期很重要,因为在公布股东名单的日期前或当天,必须完成任何该股票的交易结算。因此,如果您在6月27日或之后购买千金药业的股票,则无法在6月27日支付分红时获得分红。

The company's next dividend payment will be CN¥0.35 per share, on the back of last year when the company paid a total of CN¥0.35 to shareholders. Looking at the last 12 months of distributions, ZhuZhou QianJin PharmaceuticalLtd has a trailing yield of approximately 3.4% on its current stock price of CN¥10.20. Dividends are a major contributor to investment returns for long term holders, but only if the dividend continues to be paid. That's why we should always check whether the dividend payments appear sustainable, and if the company is growing.

该公司的下一笔股息支付将为每股CN¥0.35,在上一年公司向股东支付总共CN¥0.35的基础上。查看过去12个月的分配,千金药业的股票当前价格为CN¥10.20,其悠久回报率约为3.4%。 对于长期持有者而言,股息是投资回报的主要贡献者,但前提是股息继续支付。这就是为什么我们应该始终检查分红是否可持续,并检查公司是否在增长。

Dividends are typically paid out of company income, so if a company pays out more than it earned, its dividend is usually at a higher risk of being cut. Fortunately ZhuZhou QianJin PharmaceuticalLtd's payout ratio is modest, at just 46% of profit. A useful secondary check can be to evaluate whether ZhuZhou QianJin PharmaceuticalLtd generated enough free cash flow to afford its dividend. It distributed 34% of its free cash flow as dividends, a comfortable payout level for most companies.

分红通常是由公司收入支付的,因此,如果公司支付的分红超过它赚取的金额,其分红通常面临更高的风险。幸运的是,千金药业的派息比率非常适中,仅为利润的46%。一个有用的辅助检查是评估千金药业是否产生足够的自由现金流来支付其分红。它将其自由现金流的34%分配为分红,这对大多数公司而言是适当的派息水平。

It's positive to see that ZhuZhou QianJin PharmaceuticalLtd's dividend is covered by both profits and cash flow, since this is generally a sign that the dividend is sustainable, and a lower payout ratio usually suggests a greater margin of safety before the dividend gets cut.

值得注意的是,千金药业的股息被利润和现金流覆盖,因为这通常是该股息可持续的标志,较低的派息比率通常表明在分红被削减前较大的安全保障。

Click here to see how much of its profit ZhuZhou QianJin PharmaceuticalLtd paid out over the last 12 months.

点击此处查看千金药业过去12个月内支付了多少利润。

historic-dividend
SHSE:600479 Historic Dividend June 24th 2024
SHSE:600479历史分红记录于2024年6月24日

Have Earnings And Dividends Been Growing?

收益和股息一直在增长吗?

Companies with consistently growing earnings per share generally make the best dividend stocks, as they usually find it easier to grow dividends per share. If earnings decline and the company is forced to cut its dividend, investors could watch the value of their investment go up in smoke. With that in mind, we're encouraged by the steady growth at ZhuZhou QianJin PharmaceuticalLtd, with earnings per share up 4.5% on average over the last five years. Earnings per share growth in recent times has not been a standout. Yet there are several ways to grow the dividend, and one of them is simply that the company may choose to pay out more of its earnings as dividends.

通常,每股收益不断增长的公司通常成为最佳的股息股票,因为它们通常发现股息每股更易于增长。如果收益下降,公司被迫削减其股息,投资者可能会看着他们的投资价值干涸。因此,我们对千金药业的稳定增长感到鼓舞,过去5年,每股盈利平均增长了4.5%。近期每股收益增长尚未引人注目,但是增加股息的几种方法之一就是公司可能选择分配更多收益作为股息。

The main way most investors will assess a company's dividend prospects is by checking the historical rate of dividend growth. In the last 10 years, ZhuZhou QianJin PharmaceuticalLtd has lifted its dividend by approximately 8.8% a year on average. It's encouraging to see the company lifting dividends while earnings are growing, suggesting at least some corporate interest in rewarding shareholders.

大多数投资者评估公司的股息前景的主要方式是检查分红增长的历史速度。在过去的10年中,千金药业的分红平均每年增长约8.8%。令人鼓舞的是,该公司在盈利增长的同时提高股息,表明公司有一定的股东奖励意愿。

Final Takeaway

最后的结论

From a dividend perspective, should investors buy or avoid ZhuZhou QianJin PharmaceuticalLtd? Earnings per share growth has been growing somewhat, and ZhuZhou QianJin PharmaceuticalLtd is paying out less than half its earnings and cash flow as dividends. This is interesting for a few reasons, as it suggests management may be reinvesting heavily in the business, but it also provides room to increase the dividend in time. It might be nice to see earnings growing faster, but ZhuZhou QianJin PharmaceuticalLtd is being conservative with its dividend payouts and could still perform reasonably over the long run. Overall we think this is an attractive combination and worthy of further research.

从股息角度考虑,投资者应该购买千金药业的股票还是避免它?每股盈利增长有所增长,而千金药业的派息不到其盈利和现金流的一半。这是有趣的几个原因,因为它表明管理层可能正在大力重新投资业务,但它也为逐步增加派息提供了空间。虽然可能希望看到盈利增长更快,但千金药业在派息支出方面非常谨慎,并且可能在长期的表现方面表现得合理。总体而言,我们认为这是一种有吸引力的组合,值得进一步研究。

So while ZhuZhou QianJin PharmaceuticalLtd looks good from a dividend perspective, it's always worthwhile being up to date with the risks involved in this stock. For example - ZhuZhou QianJin PharmaceuticalLtd has 1 warning sign we think you should be aware of.

因此,尽管千金药业在股息方面看起来不错,但随时了解此股票的风险仍然值得。例如,千金药业有1个警告标志,我们认为您应该知道。

If you're in the market for strong dividend payers, we recommend checking our selection of top dividend stocks.

如果你在寻找强劲的股息支付者,我们建议查看我们的顶级股息股票选择。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有反馈?关于内容有所顾虑?直接和我们联系。或电邮 editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,也可以发送电子邮件至editorial-team@simplywallst.com

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发